Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Machine Learning Derived Three-Parameter Prognostic Model for Survival in Patients with BPDCN

Shai O. Shimony, Julia Keating, Marlise R. Luskin, Christopher Fay, Florian Renosi, Eric Deconinck, Francine Garnache-Ottou, Donna S. Neuberg, Nicole R. Leboeuf, Andrew A. Lane

Blood (2024) 144 (Supplement 1): 321.

https://doi.org/10.1182/blood-2024-198275

Published: 2024

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm Are Not Characterized By Two Distinct Subgroups, but By a Transcriptomic and Phenotypic Gradient

Florian Renosi, Ambre Giguelay, Jean Francis Berry, Evan Seffar, Sabeha Biichlé, Alexis Overs, Xavier Roussel, Guillaume Tosato, Romain Boidot, Sandy Chevrier, Zohair Selmani, Eric Deconinck, Eric Hervouet, Paul Peixoto, Francine Garnache Ottou, Jacques Colinge

Blood (2024) 144 (Supplement 1): 6106.

https://doi.org/10.1182/blood-2024-206941

Published: 2024

Journal Articles

Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model

Margaux Poussard, Morgane Boichut, Imane Belakri, Sabeha Biichle, Maxime Fredon, Florian Renosi, Francine Garnache Ottou, Krystal Watkins, Callum Mortimer Sloss, Patrick A. Zweidler-McKay, Fanny Delettre

Blood (2023) 142 (Supplement 1): 2791.

https://doi.org/10.1182/blood-2023-185602

Published: 2023

Journal Articles

Analysis of Tagraxofusp Activity in AML-Pdc As a Single Agent and in Combination with BCL2 Inhibitors

Morgane Boichut, Margaux Poussard, Imane Belakri, Xavier Roussel, Sabeha Biichle, Maxime Fredon, Florian Renosi, Eric Deconinck, Christopher Brooks, Francine Garnache Ottou, Fanny Delettre

Blood (2023) 142 (Supplement 1): 2783.

https://doi.org/10.1182/blood-2023-186126

Published: 2023

Journal Articles

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Blood (2023) 142 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2023-173379

Published: 2023

Journal Articles

Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-137727

Published: 2020

Journal Articles

A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia

Jonathan Bond, Aleksandra Krzywon, Ludovic Lhermitte, MD PhD, Christophe Roumier, PharmD, Anne Roggy, Mohamed Belhocine, PhD MSc, BSc, Alexander Kheirallah, Patrick Villarese, PhD, Guillaume Hypolite, Francine Garnache-Ottou, D.Pharm PhD, Herve Dombret, MD PhD, Nicolas Boissel, MD PhD, Claude Preudhomme, PharmD, PhD, Vahid Asnafi, MD PhD, Elisa Laurenti, PhD, Elizabeth Macintyre, PhDMD

Blood (2019) 134 (Supplement_1): 2511.

https://doi.org/10.1182/blood-2019-125902

Published: 2019

Journal Articles

LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis

Adam Ceroi, David Masson, Anne Roggy, Christophe Roumier, Cécile Chagué, Thierry Gauthier, Laure Philippe, Baptiste Lamarthée, Fanny Angelot-Delettre, Francis Bonnefoy, Sylvain Perruche, Sabeha Biichle, Claude Preudhomme, Elisabeth Macintyre, Laurent Lagrost, Francine Garnache-Ottou, Philippe Saas

Blood (2016) 128 (23): 2694–2707.

https://doi.org/10.1182/blood-2016-06-724807

Published: 2016

Includes: Supplemental data

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Harbors Frequent Splicesosome Mutations That Cause Aberrant RNA Splicing Affecting Genes Critical in pDC Differentiation and Function

Blood (2016) 128 (22): 738.

https://doi.org/10.1182/blood.V128.22.738.738

Published: 2016

Journal Articles

Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma

Mark A. Murakami, MD MA, Alexandra N. Christodoulou, M.S., Amanda L Christie, B.S., Tiffany DeSouza, B.S., Abner Louissaint, Jr., MD PhD, Una Vojinovic, B.S., Raphael Koch, MD, Loretta S. Li, MD, Scott P. Kallgren, PhD, Prakash Rao, PhD, Johannes Köster, PhD, Raga Vadhi, M.S., Eilene Duberow, B.S., Elizabeth A. Morgan, MD, Hongjun Wang, Samia S. Ahmed, Katharine L. Majewski, Marina Konopleva, MD PhD, Jerome Tamburini, MD, PhD, Alejandro Gutierrez, MD, Michelle Kelliher, PhD, Julia Etchin, PhD, Irmela Jeremias, MD, Andrew P. Weng, MD PhD, Andrew L Kung, MD PhD, Andrew A Lane, MD PhD, Francine Garnache-Ottou, PhD, Shai Izraeli, MD Prof, Eric Jacobsen, MD, Ilene Galinsky, ANP, Richard M. Stone, MD, Marian H. Harris, MD PhD, David M. Dorfman, MD PhD, Jon C Aster, MDPhD, Henry Long, PhD, Lewis B. Silverman, MD, David M Weinstock, MD

Blood (2015) 126 (23): 3252.

https://doi.org/10.1182/blood.V126.23.3252.3252

Published: 2015

Journal Articles

Liver X Receptor Agonists: A Potential Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm

Adam Ceroi, PhDSTUDENT, Francine Garnache-ottou, PhD, Anne Roggy, PhDSTUDENT, Fanny Angelot-Delettre, PhD, Laure Philippe, MDcal student, Afag Asgarova, PhDstudent, Francis Bonnefoy, PhD, Cécile Chagué, SM Student, Sabeha Biichle, Jean-Paul Remy-Martin, ING, Claude Preudhomme, MD PhD, Christophe Roumier, MD, Elizabeth Macintyre, MD PhD, Laurent Lagrost, PhD, David Masson, PhD, Philippe Saas, PhD

Blood (2015) 126 (23): 4933.

https://doi.org/10.1182/blood.V126.23.4933.4933

Published: 2015

Journal Articles

How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network

Eve Poret, Chrystelle Vidal, Yohan Desbrosses, Fanny Angelot Delettre, Maider Pagadoy, Aurore Pugin, Louis Benazet, Franck Leroux, Elise Robert, Delphine Binda, Sabeha Biichle, Anne Roggy, PhDSTUDENT, Laure Philippe, MDcal student, Berengere Gruson, Anne-Claire Gac, Michel Maigre, Denis Caillot, Remy Gressin, MD, Pascal Turlure, MD, Anne-Sophie Michallet, MD, Lila Gilis, Veronique Dorvaux, Yazid Arkam, Caroline Bonmati, MD, Pierre Péterlin, Pierre-Simon Rohrlich, MD PhD, Thorsten Braun, MD PhD, jean-Valere Malfuson, Didier Bouscary, MDPhD, Eric Pujade-Lauraine, Felipe Suarez, MD PhD, Carole Soussain, MD, Etienne Lengliné, MD, Mathieu Puyade, MD, Tony Marchand, MD, Denis Guyotat, Bruno Lioure, MD, Christian Recher, MD, Damien Roos-Weil, Fabrice Jardin, Jean-Pierre Marolleau, Bernard Drenou, MD, Bernard Bonnotte, MD PhD, Sophie Dalac, Philippe Saas, PhD, Francine Garnache Ottou, PhD, Eric Deconinck

Blood (2015) 126 (23): 456.

https://doi.org/10.1182/blood.V126.23.456.456

Published: 2015

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Amanda L Christie, B.S., Yvonne Li, PhD, Katsuhiro Togami, MD, Mahmoud Ghandi, PhD, Alexandra N. Christodoulou, M.S., Kevin Buczkowski, Fanny Angelot-Delettre, PhD, Sabeha Biichle, Janice Chen, PhD, Christopher L. Brooks, PhD, David M. Weinstock, MD, Francine Garnache-Ottou, PhD, Peter S Hammerman, MD PhD, Andrew A Lane, MD PhD

Blood (2015) 126 (23): 3797.

https://doi.org/10.1182/blood.V126.23.3797.3797

Published: 2015

Journal Articles

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Eve Poret, Fanny Angelot Delettre, Sabeha Biichle, Anne Roogy, Louis Benazet, Maider Pagadoy, Chrystelle Vidal, Franck Leroux, Véronique Harrivel, Christophe Ferrand, PhD, Veronique Salaun, Zehaira Benseddik, Julien Guy, Marie Christine Jacob, Christophe Roumier, Jean Feuillard, Liliana Vila, Lucile Baseggio, Adriana Plesa, Christine Arnoulet, B Benet, Bernard Drenou, MD, Veronique Latger Cannard, Marie-Christine Bene, MD, Michel Ticchioni, Daniel Lusina, Valerie Bardet, Magalie LE Garff Tavernier, Elizabeth Macintyre, MD PhD, Vahid Asnafi, MDPhD, Maria Elena Noguera, Sabrina Bouyer, Carine Lecoq Lafon, Mikael Roussel, MD PhD, Fabrice Jardin, Francoise Solly, MD, Lydia Campos, MD PhD, Anne Galoisy, Anne Arnaud, Sylvie Daliphard, Franck Genevieve, MD PhD, Romaric Lacroix, Françoise Schillinger, Estelle Seilles, Delphine Binda, Eric Deconinck, Philippe Saas, PhD, Francine Garnache Ottou, PhD

Blood (2015) 126 (23): 3812.

https://doi.org/10.1182/blood.V126.23.3812.3812

Published: 2015

Journal Articles

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Arthur E. Frankel, Jung H. Woo, Chul Ahn, Naveen Pemmaraju, Bruno C. Medeiros, Hetty E. Carraway, Olga Frankfurt, Stephen J. Forman, Xuezhong A. Yang, Marina Konopleva, Francine Garnache-Ottou, Fanny Angelot-Delettre, Christopher Brooks, Michael Szarek, Eric Rowinsky

Blood (2014) 124 (3): 385–392.

https://doi.org/10.1182/blood-2014-04-566737

Published: 2014

Journal Articles

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

Delettre Fanny, PhD, Arthur E. Frankel, MD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Eric Deconninck, MD, Francis Bonnefoy, PhD, Baptiste Lamarthee, PhD Student, Christopher L. Brooks, PhD, Eric Rowinsky, MD, Philippe Saas, Ph.D., Francine Garnache Ottou, PhD

Blood (2013) 122 (21): 3942.

https://doi.org/10.1182/blood.V122.21.3942.3942

Published: 2013

Journal Articles

Blastic plasmacytoid dendritic cell neoplasm

Fanny Angelot-Delettre, Francine Garnache-Ottou

Blood (2012) 120 (14): 2784.

https://doi.org/10.1182/blood-2012-03-417030

Published: 2012

Journal Articles

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells

Fanny Angelot-Delettre, PhD, Arthur E. Frankel, MD, Jen Sing Liu, PhD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Bernard Drenou, MD, PhD, Mark L. Jacobson, MA, Thomas P. Cirrito, PhD, Arkam Yazid, MD, Eric Deconinck, MD, PhD, Christopher L. Brooks, PhD, Philippe Saas, PhD, Francine Garnache Ottou, PhD

Blood (2011) 118 (21): 2588.

https://doi.org/10.1182/blood.V118.21.2588.2588

Published: 2011

Journal Articles

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance

Carole Henry, Marina Deschamps, Pierre-Simon Rohrlich, Jean-René Pallandre, Jean-Paul Rémy-Martin, Mary Callanan, Alexandra Traverse-Glehen, Camille GrandClément, Francine Garnache-Ottou, Remy Gressin, Eric Deconinck, Gilles Salles, Eric Robinet, Pierre Tiberghien, Christophe Borg, Christophe Ferrand

Blood (2010) 115 (12): 2420–2429.

https://doi.org/10.1182/blood-2009-06-229112

Published: 2010

Includes: Supplemental data

Journal Articles

A New Human CD20 Spliced mRNA as a Potential Molecular Marker for the Follow-up of B-Cell Malignancies.

Marina Deschamps, Carole Henry, Eric Robinet, Francine Garnache-Ottou, Jean-Paul Remy-Martin, Christophe Borg, Pierre-Simon Rohrlich, Eric Deconinck, Pierre Tiberghien, Christophe Ferrand

Blood (2008) 112 (11): 1479.

https://doi.org/10.1182/blood.V112.11.1479.1479

Published: 2008

NARROW

Machine Learning Derived Three-Parameter Prognostic Model for Survival in Patients with BPDCN

Blastic Plasmacytoid Dendritic Cell Neoplasm Are Not Characterized By Two Distinct Subgroups, but By a Transcriptomic and Phenotypic Gradient

Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model

Analysis of Tagraxofusp Activity in AML-Pdc As a Single Agent and in Combination with BCL2 Inhibitors

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

A Transcriptomic Continuum of Differentiation Arrest in Acute Leukemia

LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Harbors Frequent Splicesosome Mutations That Cause Aberrant RNA Splicing Affecting Genes Critical in pDC Differentiation and Function

Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma

Liver X Receptor Agonists: A Potential Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm

How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

Blastic plasmacytoid dendritic cell neoplasm

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance

A New Human CD20 Spliced mRNA as a Potential Molecular Marker for the Follow-up of B-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only